Abaris Biotech.Opportunities A EUR/ LU2210105669 /
NAV5/21/2024 | Chg.+0.0600 | Type of yield | Investment Focus | Investment company |
---|---|---|---|---|
68.6500EUR | +0.09% | reinvestment | Equity Worldwide | Hauck & Aufhäuser ▶ |
Monthly performance
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020 | - | - | - | - | - | - | - | - | - | - | - | 2.53 | - |
2021 | 7.93 | -2.72 | -8.89 | 1.73 | -8.80 | 8.90 | -7.89 | 4.55 | -3.97 | 1.19 | -12.08 | -0.29 | -20.72% |
2022 | -24.15 | 2.59 | 4.23 | -15.34 | -18.09 | 9.58 | 14.69 | 2.56 | -4.59 | -2.60 | -9.71 | -1.18 | -39.89% |
2023 | 13.48 | -5.60 | -12.56 | 3.22 | 6.96 | -2.86 | 2.34 | -7.78 | -7.20 | -17.55 | 18.37 | 30.90 | +12.38% |
2024 | 0.70 | 38.44 | -6.06 | -12.69 | 4.51 | - | - | - | - | - | - | - | - |
Calculated values
YTD | 6 Months | 1 Year | 3 Years | 5 Years | |
---|---|---|---|---|---|
Volatility | 42.23% | 42.06% | 37.73% | 41.64% | -% |
Sharpe ratio | 1.31 | 3.71 | 0.71 | -0.33 | - |
Best month | +38.44% | +38.44% | +38.44% | +38.44% | - |
Worst month | -12.69% | -12.69% | -17.55% | -24.15% | - |
Maximum loss | -21.67% | -21.67% | -36.08% | -65.54% | - |
Outperformance | - | - | - | - | - |
All quotes in EUR
Tranches
Name | Type of yield | Repurchase p. | 1 Year | 3 Years | |
---|---|---|---|---|---|
Abaris Biotech.Opportunities A C... | reinvestment | 62.3900 | +33.74% | -34.81% | |
Abaris Biotech.Opportunities A E... | reinvestment | 68.6500 | +30.49% | -26.91% | |
Abaris Biotech.Opportunities A U... | reinvestment | 62.5200 | +32.68% | -34.56% |
Performance
YTD | +19.50% | ||
---|---|---|---|
6 Months | +60.62% | ||
1 Year | +30.49% | ||
3 Years | -26.91% | ||
5 Years | - | ||
10 Years | - | ||
Since start | -31.35% | ||
Year | |||
2023 | +12.38% | ||
2022 | -39.89% | ||
2021 | -20.72% |